Stimulant treatment for adult ADHD does not inevitably worsen anxiety, but anxiety can occur as a side effect. Studies do not establish a consistent anxiety benefit, so improvement in ADHD and changes in anxiety need to be assessed separately.
Direct Answer
Stimulants are used to treat ADHD, including in people who also have anxiety. Their effect on anxiety is less predictable: anxiety may improve, remain unchanged, or worsen. The available research does not establish stimulants as treatments for anxiety disorders, and a reassuring average result in a trial does not mean that every participant felt better.
For someone with both conditions, the useful question is therefore broader than whether a stimulant is "good" or "bad" for anxiety. It includes whether ADHD symptoms improve, whether an existing anxiety disorder changes, and whether new tension or anxiety appears during treatment. These are different outcomes. The Evidence Review considers each separately because combining them can give a misleading impression of benefit or harm.
What earlier understanding suggested
There are reasonable reasons to expect either improvement or worsening. Better attention and day-to-day functioning may ease some sources of distress. At the same time, a person may feel more tense after starting a stimulant, and an anxiety disorder may still need treatment in its own right. Neither possibility tells us in advance what will happen for an individual patient.
The review does not document a simple reversal of earlier guidance. Instead, it examines why findings that appear to conflict may be measuring different experiences. An anxiety questionnaire asks about symptom severity. A side-effect report records a problem that occurred during treatment. Improvement in emotional regulation is another outcome again; it cannot automatically be counted as improvement in anxiety.
What recent evidence suggests
The review brings together controlled trials, reports of side effects, and smaller studies of adults with diagnosed anxiety disorders. Its final evidence search was conducted on October 3, 2026. It is a narrative review of selected evidence, and it does not combine the studies into a new statistical analysis.
In controlled trials, anxiety scores did not show a consistent benefit from stimulants. Some studies found little difference from placebo, some reported improvement in a particular setting, and others found higher anxiety scores during treatment. Many participants had little anxiety at the start. That limits what those studies can tell us about an adult whose anxiety disorder is active and substantially affects daily life. A result that is not statistically significant also does not prove that two treatments have the same effect.
Evidence specifically involving diagnosed anxiety disorders is more limited. Small uncontrolled studies reported improvement, but without a comparison group it is difficult to know how much was due to the stimulant rather than other treatment or changes over time. A recent conference abstract reported no observed anxiety worsening, but did not supply a numerical anxiety treatment estimate with a range showing its uncertainty. That finding remains preliminary.
Side-effect findings deserve separate attention. Anxiety was reported during both methylphenidate and amphetamine treatment. A published review found a higher risk of anxiety side effects with extended-release methylphenidate than with placebo, but rated the evidence very low certainty. That is a reason to monitor symptoms, rather than a precise prediction of any one person's risk. A stable average anxiety score can coexist with worsening in some participants.
The studies also differed in medication formulation, other treatments, follow-up, and how anxiety was recorded. The review therefore cannot reliably rank stimulant formulations by their effects on anxiety or establish their longer-term effects on an anxiety disorder.
What this means in practice
Having anxiety does not by itself mean that the usual ADHD medication choices are excluded. NICE guidance recommends the same ADHD medication choices for people with coexisting anxiety disorders, alongside slower dose adjustment and more frequent monitoring when mental health conditions are present. This supports careful ADHD treatment; it does not turn a stimulant into an established anxiety treatment.
For a discussion with a prescribing clinician, it can be useful to distinguish attention and functioning from anxiety severity and new feelings of activation. Timing matters too: whether a change followed treatment initiation or a dose increase, occurred alongside disrupted sleep, or coincided with another medication change. Those observations provide context for a clinical assessment without proving what caused the change.
I read these findings as a reason to keep the goals of treatment distinct. Improvement in ADHD does not, on its own, tell me whether anxiety has improved. I would weigh the patient's starting anxiety, changes in daily functioning, sleep, and the timing of new symptoms alongside the research. I would also distinguish an anxiety disorder that needs attention in its own right from symptoms reported as a medication side effect. The evidence supports that careful distinction, but it does not supply one medication choice that will suit everyone.
What this is and isn't
This is general educational information based on a structured review of current medical evidence. It is not a substitute for personalized medical advice. Your individual situation may differ; consult your physician for guidance specific to you.
The underlying narrative review used selected sources and targeted searches. Some findings rely on abstracts or published reviews where original full texts were unavailable. It did not include independent duplicate screening or a new formal assessment of evidence certainty.
Last reviewed by Dr. Margarita Krasnova, MD on October 5, 2026. Full review and source list: Evidence Review: Stimulant Treatment and Anxiety in Adults With ADHD.
This summary covers research published from 2001–2025. Methods, references, and limitations are in the linked Evidence Review.
If you'd like to discuss how this might apply to your own situation, that is a conversation worth having with a physician who knows you.
Dr. Krasnova provides adult ADHD treatment in Los Angeles for adults, in person and by secure telepsychiatry across California.
Contact Dr. Krasnova →